pharmaphorum| News & views on pharma and biotech’s evolving future

R&D

This week in clinical trials: 20th to 24th May

In this instalment of our renewed clinical trials round-ups, we look at life sciences research and development announced during the week of 20th to 24th May, from early-stage onwards.

News

NICE, NHS England unveil new pathway for medtech

Feedback is being sought on a proposed pathway that aims to accelerate access to new medical technologies by laying out a common set of rules and commissioning principles.

Market Access

The biosimilars dance: How drugmakers game the US patent sys...

When the primary patent on a blockbuster drug expires, affordable generic or biosimilar competition is expected to balance the market, offering relief to patients who could not afford the h

News

ASCO: AffyImmune claims a first with CAR-T for solid tumours

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy.

News

ASCO: Merus bispecific garners attention after abstract drop

Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petose

Featured Content

R&D

This week in clinical trials: 20th to 24th May

In this instalment of our renewed clinical trials round-ups, we look at life sciences research and development announced during the week of 20th to 24th May, from early-stage onwards.

Market Access

illustration of person walking from above

Chasing the holy grail of value-based healthcare

Patients, healthcare professionals, payers, and other stakeholders can have vastly different views on the value of a particular product, often resulting in a struggle between prioritising a

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Sponsored

PDURS explained: The FDA’s new framework for adding software...

The US FDA has recently proposed a new draft framework that enables pharma manufacturers to add software to a drug label if they can demonstrate that the software adds clinical benefit to t

R&D

Challenges and opportunities in synthetic clinical trials

Of the many changes coming to clinical trials, one of the biggest potential paradigm shifts on the horizon is the elimination of placebo groups in some trials in favour of synthetic control

R&D

Eloise McLennan interview with Peter Stenico

Reuters Pharma Europe 2024 – Peter Stenico

Pioneering access to biosimilars is crucial for strengthening health equity by providing affordable, life-changing therapies to patients worldwide.

Digital

HEALTHINKERS white paper download banner

Sponsored

Digital health innovation: Applications across the patient j...

Digital health innovation (DHI) is a growing category of technologies that connect healthcare stakeholders and improve patient experiences and outcomes.

Newsletters and Deep Dive
digital magazine

Latest News

News

NICE, NHS England unveil new pathway for medtech

Feedback is being sought on a proposed pathway that aims to accelerate access to new medical technologies by laying out a common set of rules and commissioning principles.

News

ASCO: AffyImmune claims a first with CAR-T for solid tumours

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy.

News

ASCO: Merus bispecific garners attention after abstract drop

Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petose

News

ADC developer Pheon raises $120m, and other bio financings

This week’s round-up of biotech financings is led by a $120 million round for UK-based antibody-drug conjugate (ADC) developer Pheon, with SixPeaks also pulling in nine fi

Views & Analysis

R&D

This week in clinical trials: 20th to 24th May

In this instalment of our renewed clinical trials round-ups, we look at life sciences research and development announced during the week of 20th to 24th May, from early-stage onwards.

Market Access

Collaboration is key to tackling geographical boundaries in ...

Unlike most biopharmaceuticals, it is often a struggle to manufacture cell and gene therapies (CGTs) in disparate geographies.

Market Access

Which companies will last? Success begins with the basics

Founding a new company is a high stakes business. Many leaders begin with an exciting, well-funded solution and then struggle to build a sustainable business over time.

R&D

Challenges and opportunities in synthetic clinical trials

Of the many changes coming to clinical trials, one of the biggest potential paradigm shifts on the horizon is the elimination of placebo groups in some trials in favour of synthetic control

Deep Dive

Market Access

The biosimilars dance: How drugmakers game the US patent sys...

When the primary patent on a blockbuster drug expires, affordable generic or biosimilar competition is expected to balance the market, offering relief to patients who could not afford the h

Market Access

Rare diseases: the urgent need for health equity and acceler...

Rare diseases are complex, but the need is urgent. Alexion’s Eunice Alvazzi discusses the shared responsibility in achieving access to innovation in rare diseases

Market Access

Chasing the holy grail of value-based healthcare

Patients, healthcare professionals, payers, and other stakeholders can have vastly different views on the value of a particular product, often resulting in a struggle between prioritising a

Market Access

Deep Dive: Market Access 2024

In this edition of Deep Dive, Unpacking complex choreography in the biologics patent dance, Alexion examines the urgent need for accelerated access programmes for rare disease treatments, and Putna

White Papers & Webinar

Digital

Sponsored

Digital health innovation: Applications across the patient j...

Digital health innovation (DHI) is a growing category of technologies that connect healthcare stakeholders and improve patient experiences and outcomes.

Digital

Sponsored

PDURS explained: The FDA’s new framework for adding software...

The US FDA has recently proposed a new draft framework that enables pharma manufacturers to add software to a drug label if they can demonstrate that the software adds clinical benefit to t

Sales & Marketing

M3 - 10 Data trends white paper download banner

Sponsored

How doctors are interacting with content in 10 data trends

It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Innovation as Strategy webinar: Enabling life sciences of the future

Sponsored

Innovation as Strategy: Enabling life sciences of the future

Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.

Podcasts & Video

R&D

Challenges and opportunities in synthetic clinical trials

Of the many changes coming to clinical trials, one of the biggest potential paradigm shifts on the horizon is the elimination of placebo groups in some trials in favour of synthetic control

Digital

The commercialisation of quantum science in pharma

In today’s podcast, web editor Nicole Raleigh speaks with PASQAL’S technical business developer Europe, Krisztian Benyo, PhD, about the pharma applications and co

Patients

Conference report: Reuters Pharma Europe

In this special edition of the pharmaphorum podcast, the tables have turned as Jonah Comstock puts edito

R&D

pharmaphorum podcast episode 132a - woman on her phone listening to headphones

In vitro gametogenesis: the science has to be right, and it ...

In vitro gametogenesis (IVG) holds much potential for same-sex couples and women of a more advanced age struggling with infertility, but the question is whether we’re quite there yet.

The PM Society and Word Monster are joining forces in a new partnership focusing on raising standards and nurturing talent in the MedComms industry.

Featured Content

Editor's Picks

Latest News

Views & Analysis

Deep Dive

White Papers & Webinar

Podcasts & Video

Partner Content